BioCardia reported financial results for fiscal year 2024, with net loss narrowing to $7.9 million from $11.6 million in 2023. Revenue decreased to $58,000 from $477,000 year-over-year, while operating expenses reduced significantly to $8.1 million from $12.1 million, driven by lower research and development costs following completion of the CardiAMP Cell Therapy Heart Failure Trial.The company completed enrollment in its pivotal CardiAMP Cell Therapy Heart Failure Trial, with principal results scheduled for presentation at the ACC Scientific Sessions on March 30, 2025. BioCardia also initiated the CardiAMP Heart Failure II Trial targeting 250 patients and advanced its CardiAMP Chronic Myocardial Ischemia Trial. The low-dose cohort of the CardiALLO allogeneic cell therapy trial was completed with no safety issues reported.As of December 31, 2024, BioCardia had cash and equivalents of $2.4 million, which management believes will fund operations through May 2025. The company raised $9.3 million in 2024 through equity offerings, including a $7.2 million registered offering in September. Management indicated additional funding will be required to advance clinical programs and continue operations beyond May 2025.

BioCardia reported financial results for fiscal year 2024, with net loss narrowing to $7.9 million from $11.6 million in 2023. Revenue decreased to $58,000 from $477,000 year-over-year, while operating expenses reduced significantly to $8.1 million from $12.1 million, driven by lower research and development costs following completion of the CardiAMP Cell Therapy Heart Failure Trial.The company completed enrollment in its pivotal CardiAMP Cell Therapy Heart Failure Trial, with principal results scheduled for presentation at the ACC Scientific Sessions on March 30, 2025. BioCardia also initiated the CardiAMP Heart Failure II Trial targeting 250 patients and advanced its CardiAMP Chronic Myocardial Ischemia Trial. The low-dose cohort of the CardiALLO allogeneic cell therapy trial was completed with no safety issues reported.As of December 31, 2024, BioCardia had cash and equivalents of $2.4 million, which management believes will fund operations through May 2025. The company raised $9.3 million in 2024 through equity offerings, including a $7.2 million registered offering in September. Management indicated additional funding will be required to advance clinical programs and continue operations beyond May 2025.